Paolo Del Barba Federica Del Tedesco Giulio Frontino Maria Pia Guarneri Riccardo Bonfanti Graziano Barera
10.3389/fimmu.2022.853561
Front Immunol
2022 Apr 12;13:853561.
chronic spontaneous urticaria glycemic omalizumab pediatrics type 1 diabetes
CC BY
https://pubmed.ncbi.nlm.nih.gov/35493474/
Anti-Allergic Agents / adverse effects Chronic Urticaria / diagnosis Chronic Urticaria / drug therapy Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 1 / drug therapy
Anti-Allergic Agents / adverse effects Chronic Urticaria / diagnosis Chronic Urticaria / drug therapy Diabetes Mellitus, Type 1 / complications Diabetes Mellitus, Type 1 / drug therapy Case Reports Adolescent Child Chronic Disease Female Humans Omalizumab / adverse effects Anti-Allergic Agents Omalizumab
PMC9039355
35493474
Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes
2022